Page 156 - 2019年1月第30卷第2期

pair and the DNA damage checkpoints[J]. Annu Rev Bio- 7643981.
chem，2004. DOI：10/1146/annurev.biochem.73.011303.373 [27] 韩巴特尔.GSTs 以及 XRCC1 基因多态性与非小细胞肺
723. 癌晚期铂类药物化疗疗效的关系[D].广州：南方医科大
[14] GARCÍA-CAMPELO R，ALONSO-CURBERA G，AN- 学，2016.
TÓN APARICIO LM，et al. Pharmacogenomics in lung [28] 李俊，毛伟敏.ERCC2/XPD 基因多态性与肺癌风险的研
cancer：an analysis of DNA repair gene expression in pa- 究进展[J].浙江实用医学，2008，13（2）：143-146.
tients treated with platinum-based chemotherapy[J]. Ex- [29] FISHBURN J，TOMKO E，GALBURT E，et al. Double-
pert Opin Pharmacother，2005，6（12）：2015-2026. stranded DNA translocase activity of transcription factor
[15] JALAL S，EARLEY JN，TURCHI JJ. DNA repair：from TFⅡH and the mechanism of RNA polymerase Ⅱ open
genome maintenance to biomarker and therapeutic target complex formation[J]. Proc Natl Acad Sci U S A，2015，
[J]. Clin Cancer Res，2011，17（22）：6973-6984. 112（13）：3961-3966.
[16] FUJII T，TOYOOKA S，ICHIMURA K，et al. ERCC1 pro- [30] ZHOU M，DING YJ，FENG Y，et al. Association of xero-
tein expression predicts the response of cisplatin-based derma pigmentosum group D（Asp312Asn，Lys751Gln）
neoadjuvant chemotherapy in non-small-cell lung cancer and cytidine deaminase（Lys27Gln，Ala70Thr）polymor-
[J]. Lung Cancer，2008，59（3）：377-384. phisms with outcome in Chinese non-small cell lung can-
[17] ALTAHA R，LIANG X，YU JJ，et al. Excision repair cross cer patients treated with cisplatin-gemcitabine[J]. Genet
complementing-group 1：gene expression and platinum re- Mol Res，2014，13（2）：3310-3318.
sistance[J]. Int J Mol Med，2004，14（6）：959-970. [31] LI XD，HAN JC，ZHANG YJ，et al. Common variations
[18] ARORA S，HEYZA J，ZHANG H，et al. Identification of of DNA repair genes are associated with response to plati-
small molecule inhibitors of ERCC1-XPF that inhibit num-based chemotherapy in NSCLCs[J]. Asian Pac J
DNA repair and potentiate cisplatin efficacy in cancer cells Cancer Prev，2013，14（1）：145-148.
[J]. Oncotarget，2016，7（46）：75104-75117. [32] LI P，WANG YD，CHENG J，et al. Association between
[19] 周国仁，叶劲军，冯继锋，等.核苷酸切除修复交叉互补组 polymorphisms of BAG-1 and XPD and chemotherapy
基因 1 单核苷酸多态性与晚期非小细胞肺癌患者铂类 sensitivity in advanced non-small-cell lung cancer patients
药物化疗预后的关系[J].肿瘤研究与临床，2013，25（8）： treated with vinorelbine combined cisplatin regimen[J].
523-526. Tumour Biol，2015，36（12）：9465-9473.
[20] SULLIVAN I，SALAZAR J，MAJEM M，et al. Pharmaco- [33] QIN Q，ZHANG C，YANG X，et al. Polymorphisms in
genetics of the DNA repair pathways in advanced non- XPD gene could predict clinical outcome of platinum-
small cell lung cancer patients treated with platinum-based based chemotherapy for non-small cell lung cancer pa-
chemotherapy[J]. Cancer Lett，2014，353（2）：160-166. tients：a meta-analysis of 24 studies[J]. PLoS One，2013，8
[21] 张增利，朱晓良，陈婷，等.DNA修复基因ERCC1多态性 （11）：e79864.
与晚期肺腺癌患者接受含铂方案化疗疗效的关系[J].江 [34] QIU M，YANG X，HU J，et al. Predictive value of XPD
苏医药，2015，41（21）：2524-2526. polymorphisms on platinum-based chemotherapy in non-
[22] 陈金鸣，孟晓晖，魏霞，等.ERCC1 基因多态与铂类联合 small cell lung cancer：a systematic review and meta-anal-
方案治疗肺鳞癌患者疗效的关系[J].实用癌症杂志， ysis[J]. PLoS One，2013，8（8）：e72251.
2016，31（5）：711-716. [35] 周立霞.ERCC5（XPG）在非小细胞肺癌中的表达与铂类
[23] ZHAO X，ZHANG Z，YUAN Y，et al. Polymorphisms in 耐药性的关系[D].锦州：辽宁医学院，2011.
ERCC1 gene could predict clinical outcome of platinum- [36] BOWDEN NA. Nucleotide excision repair：why is it not
based chemotherapy for non-small cell lung cancer pa- used to predict response to platinum-based chemotherapy?
tients[J]. Tumour Biol，2014，35（8）：8335-8341. [J]. Cancer Lett，2014，346（2）：163-171.
[24] HUANG SJ，WANG YF，JIN ZY，et al. Role of ERCC1 [37] ZHANG T，SUN J，LV M，et al. XPG is predictive gene of
variants in response to chemotherapy and clinical out- clinical outcome in advanced non-small-cell lung cancer
come of advanced non-small cell lung cancer[J]. Tumour with platinum drug therapy[J]. Asian Pac J Cancer Prev，
Biol，2014，35（5）：4023-4029. 2013，14（2）：701-705.
[25] YANG Y，XIAN L. The association between the ERCC1/2 [38] JIN ZY，ZHAO XT，ZHANG LN，et al. Effects of poly-
polymorphisms and the clinical outcomes of the plati- morphisms in the XRCC1，XRCC3，and XPG genes on
num-based chemotherapy in non-small cell lung cancer clinical outcomes of platinum-based chemotherapy for
（NSCLC）：a systematic review and meta-analysis[J]. Tu- treatment of non-small cell lung cancer[J]. Genet Mol Res，
mour Biol，2014，35（4）：2905-2921. 2014，13（3）：7617-7625.
[26] HAN Y，LIU J，SUN M，et al. A significant statistical ad- [39] FAN X，XIU Q. Effect of X-ray repair cross complement-
vancement on the predictive values of ERCC1 polymor- ing group 1 polymorphisms on the efficacy of platinum-
phisms for clinical outcomes of platinum-based chemo- based chemotherapy in patients with nonsmall cell lung
therapy in non-small cell lung cancer：an updated Me- cancer[J]. J Cancer Res Ther，2015，11（3）：571-574.
ta-analysis[J]. Dis Markers，2016. DOI：10.1155/2016/ [40] EL-KHAMISY SF，MASUTANI M，SUZUKI H，et al. A

中国药房 2019年第30卷第2期 China Pharmacy 2019 Vol. 30 No. 2 ·287 ·